Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a multi-pronged strategy that combines a novel DNA damage response inhibitor, a nanoparticle delivery system, and artificial intelligence to tackle three persistent challenges in cancer drug development: resistance, trial failures, and toxicity. The company's lead candidate, ONC010, targets Polynucleotide Kinase 3'-Phosphatase (PNKP), a distinct enzyme in the DNA repair pathway, differentiating it from PARP inhibitors that have dominated the field. By inhibiting PNKP, ONC010 aims to block a key mechanism cancer cells use to repair damage from radiation and chemotherapy, potentially overcoming resistance that limits current therapies.
To improve drug delivery and reduce toxicity, Onco-Innovations has paired ONC010 with a proprietary nanoparticle system designed to enhance tumor targeting and minimize systemic side effects. This approach addresses the common problem of promising drugs failing due to poor bioavailability or off-target effects. The company is currently conducting IND-enabling studies, manufacturing scale-up, and regulatory preparations to advance ONC010 toward clinical trials.
Complementing its biological and delivery innovations, Onco-Innovations leverages artificial intelligence through its subsidiary Inka Health and the SynoGraph causal AI platform. These tools are intended to support patient stratification, optimize clinical trial design, and generate real-world evidence. AI-driven analysis can help identify which patients are most likely to respond to PNKP inhibition, potentially increasing trial success rates and accelerating development timelines.
The integration of these three frontiers—novel biology, advanced delivery, and AI—reflects a broader trend in oncology toward more precise and efficient drug development. As precision oncology increasingly relies on biomarker-driven therapies, companies that can combine multiple innovative technologies may be better positioned to address the complexity of cancer. Onco-Innovations' approach could serve as a model for tackling the interconnected challenges of resistance, trial design, and toxicity.
For more information about Onco-Innovations, visit the company's newsroom at ibn.fm/ONNVF. About InvestorWire: InvestorWire is a specialized communications platform for press release syndication, part of the IBN dynamic brand portfolio. It provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release distribution, and social media reach to millions of followers. For more details, see InvestorWire.com and the disclaimer at InvestorWire.com/Disclaimer.
